Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, has scheduled a webcast for May 14, 2025, at 4:30 p.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, has scheduled a webcast for May 14, 2025, at 4:30 p.m. Eastern Time. During the webcast, the company will discuss its financial results for the first quarter ended March 31, 2025, and provide a business update.
The webcast will be accessible through the company's investor relations website, and a replay will be available for approximately 90 days following the event. Belite Bio specializes in developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
Details
News Market Reaction – BLTE
The recorded move for BLTE in the trading session of this news was +0.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025.
Webcast Information
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/137642555
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.